# Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities

> **NCT06997198** · PHASE4 · NOT_YET_RECRUITING · sponsor: **University Hospitals Cleveland Medical Center** · enrollment: 25 (estimated)

## Conditions studied

- Tardive Dyskinesia
- Intellectual Disability
- Developmental Disabilities

## Interventions

- **DRUG:** Deutetrabenazine Oral Capsule

## Key facts

- **NCT ID:** NCT06997198
- **Lead sponsor:** University Hospitals Cleveland Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06997198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06997198, "Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06997198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*